Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ADMA Biologics Inc - Common Stock
(NQ:
ADMA
)
18.23
+0.02 (+0.11%)
Streaming Delayed Price
Updated: 12:05 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ADMA Biologics Inc - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
ADMA BIOLOGICS INC (NASDAQ:ADMA) - A Strong Growth Candidate Meeting Minervini's Criteria
June 13, 2025
ADMA Biologics (NASDAQ:ADMA) meets Minervini’s Trend Template with strong technicals and high-growth fundamentals, making it a candidate for momentum investors.
Via
Chartmill
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Strong Growth Stock with Technical Breakout Potential
June 09, 2025
ADMA Biologics (NASDAQ:ADMA) shows strong growth fundamentals and a technical breakout setup, making it a stock to watch in the biotech sector.
Via
Chartmill
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A High Growth Momentum Stock with Strong Technical Setup
June 07, 2025
ADMA Biologics (NASDAQ:ADMA) shows strong earnings momentum and a favorable technical setup, making it a candidate for high-growth investors. The stock has outperformed peers and may present a breakout...
Via
Chartmill
How Is The Market Feeling About ADMA Biologics?
June 04, 2025
Via
Benzinga
ADMA BIOLOGICS INC (NASDAQ:ADMA) – A Promising Affordable Growth Stock
June 03, 2025
ADMA Biologics (NASDAQ:ADMA) shows strong growth, reasonable valuation, and solid financial health, making it an attractive candidate for investors seeking affordable growth stocks in the biotech...
Via
Chartmill
ADMA BIOLOGICS INC (NASDAQ:ADMA) is not too expensive for the growth it is showing.
May 09, 2025
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...
Via
Chartmill
Earnings Scheduled For May 7, 2025
May 07, 2025
Via
Benzinga
ADMA Biologics Earnings Preview
May 06, 2025
Via
Benzinga
What's Driving the Market Sentiment Around ADMA Biologics?
March 11, 2025
Via
Benzinga
Crude Oil Gains Over 2%; US Foods Posts Downbeat Earnings
May 08, 2025
Via
Benzinga
Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits
May 08, 2025
The company makes immunoglobulin products using donated plasma.
Via
Investor's Business Daily
Topics
Earnings
ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update
May 07, 2025
From
ADMA Biologics, Inc.
Via
GlobeNewswire
3 Mid-Cap Medical Stocks Outperforming the Market
May 06, 2025
Several mid-cap medical stocks, such as ADMA, PEN, and TMDX, are outperforming in 2025, showing resilience despite broader market weakness.
Via
MarketBeat
Topics
Economy
Should you consider ADMA BIOLOGICS INC (NASDAQ:ADMA) for growth investing?
May 05, 2025
A fundamental analysis of (NASDAQ:ADMA): Exploring growth characteristics of ADMA BIOLOGICS INC (NASDAQ:ADMA).
Via
Chartmill
Would Mark Minervini consider ADMA BIOLOGICS INC (NASDAQ:ADMA) a top stock pick?
May 01, 2025
A fundamental and technical analysis of (NASDAQ:ADMA): Exploring ADMA BIOLOGICS INC (NASDAQ:ADMA)'s high growth characteristics.
Via
Chartmill
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate
May 01, 2025
ADMA Biologics Inc (NASDAQ:ADMA): A Strong Minervini Trend Template Candidate
Via
Chartmill
ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025
April 30, 2025
Conference Call Scheduled for May 7, 2025, at 4:30 p.m. ET
From
ADMA Biologics, Inc.
Via
GlobeNewswire
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
April 29, 2025
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:POAI),(NASDAQ:ADMA) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Artificial Intelligence
What's Going On With ADMA Stock Monday?
April 28, 2025
ADM shares are trading higher Monday after the company announced the FDA's approval of its yield enhancement process.
Via
Benzinga
Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth
April 29, 2025
From
FN Media Group LLC
Via
GlobeNewswire
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday
April 28, 2025
Via
Benzinga
IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval
April 28, 2025
The company says a new process will improve its output by 20%, benefitting revenue and earnings later this year.
Via
Investor's Business Daily
ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process
April 28, 2025
From
ADMA Biologics, Inc.
Via
GlobeNewswire
Why ADMA BIOLOGICS INC (NASDAQ:ADMA) qualifies as a high growth stock.
April 23, 2025
A fundamental and technical analysis of (NASDAQ:ADMA): Is ADMA BIOLOGICS INC (NASDAQ:ADMA) suited for high growth investing?
Via
Chartmill
Investors seeking growth at a reasonable cost should explore ADMA BIOLOGICS INC (NASDAQ:ADMA).
April 16, 2025
Discover ADMA BIOLOGICS INC, an undervalued growth gem. NASDAQ:ADMA is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...
Via
Chartmill
ADMA Biologics Statement on Tariffs
April 07, 2025
Reiterates Strategic Advantage Through Fully U.S.-Based Manufacturing Operations, Commercialization and End-Market Sales, and Vertically Integrated U.S.-Based Supply Chain
From
ADMA Biologics, Inc.
Via
GlobeNewswire
What's Driving the Market Sentiment Around ADMA Biologics?
April 02, 2025
Via
Benzinga
ADMA BIOLOGICS INC (NASDAQ:ADMA) is showing good growth, while it is not too expensive.
March 20, 2025
NASDAQ:ADMA is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.
Via
Chartmill
Adma Biologics' Retail Traders Eye Higher Open After Blowout Q4, Strong Full-Year Outlook
March 03, 2025
CEO Adam Grossman highlighted a 65% year-over-year jump in total revenue and a staggering 309% increase in adjusted EBITDA for 2024.
Via
Stocktwits
ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 03, 2025
From
ADMA Biologics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.